Dashboard
With a fall in Net Profit of -29.18%, the company declared Very Negative results in Sep 26
- The company has declared negative results for the last 4 consecutive quarters
- PAT(Q) At Rs 202.60 cr has Fallen at -29.2% (vs previous 4Q average)
- NET SALES(Latest six months) At Rs 1,702.50 cr has Grown at -36.75%
- ROCE(HY) Lowest at 7.27%
Stock is technically in a Mildly Bearish range
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 16,177 Cr (Small Cap)
19.00
40
0.65%
-0.05
8.48%
1.65
Total Returns (Price + Dividend) 
Latest dividend: 1.25 per share ex-dividend date: Nov-19-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Natco Pharma Ltd: Valuation Shifts Signal Changing Price Attractiveness Amid Sector Dynamics
Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, signalling a notable change in price attractiveness. This article analyses the recent valuation metrics, compares them with peer averages, and examines the implications for investors amid evolving market dynamics.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 November 2026, providing investors with the latest insights into the company’s fundamentals, returns, and market standing.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
18-Nov-2026 | Source : BSEQ2FY27 Earnings Conference Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16-Nov-2026 | Source : BSEIntimation of Investor Meet
Announcement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSENewspaper publication for Unaudited Financail Results for the Qaurter and Half year ended September 30 2026 and Record date for the 2nd Interim Dividend for the FY ending 2026-27
Corporate Actions 
No Upcoming Board Meetings
Natco Pharma Ltd. has declared 62% dividend, ex-date: 19 Nov 26
Natco Pharma Ltd. has announced 2:10 stock split, ex-date: 26 Nov 15
No Bonus history available
Natco Pharma Ltd. has announced 2:21 rights issue, ex-date: 01 Oct 26
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Oct 2026
Shareholding Compare (%holding) 
Promoters
0.9374
Held by 24 Schemes (7.01%)
Held by 213 FIIs (15.36%)
V C Nannapaneni (15.66%)
Belgrave Investment Fund (2.31%)
22.78%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 31.57% vs -0.53% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -1.89% vs -22.92% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -1.53% vs 25.87% in Sep 2024
Growth in half year ended Sep 2025 is -25.76% vs 70.51% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 4.07% vs 9.49% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -22.19% vs 47.58% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -7.93% vs 10.77% in Mar 2025
YoY Growth in year ended Mar 2026 is -24.76% vs 35.81% in Mar 2025